2 active not recruiting, 2 completed, 2 terminated, 1 recruiting. 3 Phase 3, 2 Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Primary Peritoneal Transitional Cell Carcinoma: new trials by email Literature Review of Primary Peritoneal Transitional Cell Carcinoma trials Research Report on Primary Peritoneal Transitional Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
Ovarian Neoplasms (5) · Fallopian Tube Neoplasms (4) · Brenner Tumor (3) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Carcinoma (1) · Neoplasms (1)
Adnexal Diseases (6) · Endocrine System Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Gonadal Disorders (6) · Ovarian Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Endocrine Gland Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Fallopian Tube Diseases (4)
Bevacizumab (4) · Disulfides (4) · Immunoglobulin G (4) · Taxes (4) · Paclitaxel (3) · Carboplatin (2) · Doxorubicin (2) · Gemcitabine (2) · liposomal doxorubicin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Cisplatin (1) · Docetaxel (1) · Drug Therapy (1)
National Cancer Institute (NCI) (3) · Mayo Clinic (2) · M.D. Anderson Cancer Center (1) · University of Washington (1)
United States (7) · Canada (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · South Korea (1)
Evanthia Galanis, M.D. (1) · Joan L Walker (1) · Jose A Rauh-Hain (1) · Kathryn Pennington (1) · Matthew S. Block, M.D., Ph.D. (1) · Rachel N Grisham (1) · Robert L Coleman (1)
PMID 28438473, PMID 31002578, PMID 31722153, PMID 37185961, PMID 39570589
U10CA027469 (2), U10CA180868 (2), R21CA215662 (1), UM1CA186691 (1)